Key facts
- This page summarizes Thomas R. Cannell's Form 4 filing for Sesen Bio, Inc. (CARM).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2023, 19:43.
Thomas R. Cannell - 02 Mar 2023 Form 4 Insider Report for Sesen Bio, Inc. (CARM)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- CARM
- Reported as of
- 02 Mar 2023
- Net transaction value
- +$70,037
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 19:43:40 UTC
- Prior SEC filing
- 23 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas R. Cannell
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas R. Cannell filed Form 4 for Sesen Bio, Inc. (CARM) on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: +$70,037.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARM
transaction
Common Stock
Sale
- Transaction value
- $122,638
- Shares
- -208,923
- Change %
- -38%
- Price
- $0.5870*
- Shares after
- 344,150
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CARM
transaction
Common Stock
Options Exercise
- Transaction value
- $356,192
- Shares
- +606,800
- Change %
- +176%
- Price
- $0.5870*
- Shares after
- 950,950
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F3
CARM
transaction
Common Stock
Sale
- Transaction value
- $163,517
- Shares
- -278,564
- Change %
- -29%
- Price
- $0.5870*
- Shares after
- 672,386
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
Footnote F3
Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
Footnote F4
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.